REGENXBIO Secures $70.5 Million in a Mezzanine Financing
May 20, 2015 07:30 ET
|
REGENXBIO Inc.
ROCKVILLE, Md., May 20, 2015 (GLOBE NEWSWIRE) -- REGENXBIO Inc., a leading biotechnology company in gene therapy, today announced the successful completion of a heavily oversubscribed $70.5 million...
Luke M. Beshar Appointed to REGENXBIO Board of Directors
April 28, 2015 09:00 ET
|
REGENXBIO Inc.
ROCKVILLE, Md., April 28, 2015 (GLOBE NEWSWIRE) -- REGENXBIO Inc., a leading biotechnology company in gene therapy, today announced that Luke M. Beshar has been appointed to its board of directors...
REGENXBIO and Dimension Therapeutics Add Development of Treatments for Two Metabolic Diseases to Exclusive License Agreement
April 23, 2015 08:00 ET
|
REGENXBIO Inc.
ROCKVILLE, Md., April 23, 2015 (GLOBE NEWSWIRE) -- REGENXBIO Inc., a leading biotechnology company in gene therapy, today announced that it has added the indications of ornithine transcarbamylase...
REGENXBIO Licenses Key Technologies From University of Pennsylvania and University of Minnesota for the Development of Treatments for MPS I and MPS II
April 08, 2015 09:00 ET
|
REGENXBIO Inc.
WASHINGTON, April 8, 2015 (GLOBE NEWSWIRE) -- REGENXBIO Inc., a leading biotechnology company in gene therapy, today announced that it has entered into separate license and research agreements with...
REGENXBIO Raises $30 Million in Series C Financing
January 21, 2015 07:30 ET
|
REGENXBIO Inc.
WASHINGTON, Jan. 21, 2015 (GLOBE NEWSWIRE) -- REGENXBIO Inc., a leading biotechnology company in gene therapy, today announced the completion of a $30 million Series C financing. Venrock and Brookside...
REGENXBIO to Present at 26th Annual Piper Jaffray Healthcare Conference
November 25, 2014 09:00 ET
|
REGENXBIO Inc.
WASHINGTON, Nov. 25, 2014 (GLOBE NEWSWIRE) -- REGENXBIO Inc. today announced that Ken Mills, President and Chief Executive Officer, will present a company overview at the 26th Annual Piper Jaffray...
Dr. James M. Wilson Joins REGENXBIO as Chief Scientific Advisor
November 18, 2014 09:00 ET
|
REGENXBIO Inc.
WASHINGTON, Nov. 18, 2014 (GLOBE NEWSWIRE) -- REGENXBIO Inc. today announced that James M. Wilson, M.D., Ph.D. has been named its Chief Scientific Advisor, effective immediately. Dr. Wilson is also...
REGENXBIO Appoints Dr. Stephen Yoo as Chief Medical Officer
October 28, 2014 09:00 ET
|
REGENXBIO Inc.
WASHINGTON, Oct. 28, 2014 (GLOBE NEWSWIRE) -- REGENXBIO Inc. today announced the appointment of Stephen Yoo, M.D. as Chief Medical Officer, effective immediately. Dr. Yoo will oversee the development...
REGENXBIO's NAV(R) Technology Demonstrates Correction of Cardiovascular Symptoms of MPS I in Animal Model
September 29, 2014 16:30 ET
|
REGENXBIO Inc.
WASHINGTON, Sept. 29, 2014 (GLOBE NEWSWIRE) -- REGENXBIO Inc. today announced that gene transfer mediated by REGENXBIO's NAV® AAV8 vectors resulted in sustained serum α-L-iduronidase (IDUA)...
Study Using REGENX Biosciences' NAV(R) Vector Highlights Potential for AAV-Mediated Gene Therapy to Treat Lysosomal Storage Diseases That Affect the CNS
August 27, 2014 06:30 ET
|
REGENXBIO Inc.
Results support REGENX's plans to advance gene therapies for MPS I and MPS II into human clinical trials
WASHINGTON, Aug. 27, 2014 (GLOBE NEWSWIRE) -- REGENX Biosciences, LLC today announced...